Most MDS patients have at least one oncogenic mutation, with splicing factor mutations occurring in >50% of patients (Papaemmanuil et al., 2013), including SF3B1, SRSF2, U2AF1 and ZRSR2. This evidence concerns the gene SLU7 and myelodysplastic syndrome.